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Abstract 
 
Objective: The objective of this selective EBM review is to determine whether or not the use of 
antidepressants improves the quality of life and decreases the severity of symptoms in patients 
with IBS.  
 
Study Design: Review of three English language, double-blind, randomized controlled trials 
published in 2009. 
 
Data sources: Randomized controlled trials comparing the use of three different antidepressants 
to a controlled placebo were found on PubMed, OVID and the Cochrane database. 
 
Outcome(s) Measured: Primary end point was overall bowel symptom score at the end of 
twelve weeks. Secondary end points include individual BSS for each irritable bowel syndrome 
subset, constipation, pain, or discomfort. Other secondary end points assessed adequate relief of 
symptoms, IBS-quality of life, and rectal sensitivity. Outcomes were measured through the use 
of questionnaires. 
 
Results: Three randomized controlled trials were included in this review. The study by Abdul-
Baki H. indicated that imipramine was superior to treating IBS when compared to placebo, 
making this the only therapy evaluated in this review to be effective. Study by Ladabaum U. 
indicated that citalopram was less effective than placebo. Study by Saito Y. determined that St. 
John’s Wort was less effective than placebo in decreasing symptoms of IBS. 
 
Conclusions: The results of the study using imipramine concluded that the drug was effective in 
reducing symptoms and improving quality of life for patients with IBS. The other two studies 
concluded that the therapy drugs were less effective than the placebo in treating symptoms of 
IBS. The population studied in some of the studies was not very large and one study had a 
majority of females which are factors that should be changed in future studies. 
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Introduction 
Irritable bowel syndrome (IBS) is a condition that causes abdominal pain which affects 
approximately 10-15% of the adult population.
1
 IBS is defined by the Rome II criteria and is 
characterized by constipation, diarrhea, or an alternation of the two. It is also defined by the 
presence of abdominal pain, fullness, bloating, and relief after defecation present for at least 
three days per month for the past three consecutive months.
1 
In recent years, there has been a 
dramatic rise of the diagnosis of IBS due to increased awareness of the condition. While it is 
estimated that 10-15% of the adult population is affected by IBS, only 50% of patients with 
symptoms search for aid. 
2
  
The epidemiology of the condition may depend on where the patient lives or the regional 
culture in regards to healthcare. For example, in the United States, women are more likely to be 
effected or report symptoms. However, men are more likely to be effected in India and Sri 
Lanka.
2
 The pathophysiology of IBS is still unclear, which is why there is so much research 
being done for treatment options.
1
This paper evaluates three RCTs studying the effectiveness of 
antidepressants in decreasing symptoms and improving quality of life for patients with IBS. 
The total cost for IBS patients in the United States for health care 21.5 billion dollars a 
year.
3
 The cost in the first year of healthcare for IBS diagnosis is $4,044 and the sum of all 
patients lose 205 million dollars from lost work days due to either the condition itself or days 
spent seeking healthcare.
3
 There was an average of approximately 3.65 million visits a year 
between 1998-2000 for patients with IBS.
3 
There is not much that is known for certain about the 
condition. In recent studies, it was found that up to 80% of patients with IBS have an associated 
psychiatric etiology.
 1
There are many theories regarding what initiates IBS and how the 
condition produces symptoms, however, the exact physiology of the condition is unknown. Some 
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hypotheses believe that there may be disturbance of motility, gastrointestinal (GI) changes from 
infection, or altered perception of pressure in the GI tract.
1
 
 Researchers have determined that the pathophysiology is based on the individual.  In 
some individuals, it has been found that there is increased activity of the prefrontal lobe with 
colonic activity.
 1
Therefore, indicating that these patients may have increased sensitivity and 
awareness of abdominal discomfort.  In other studies it was found that serotonin plays a large 
role in symptomatology of IBS. Serotonin is released into the gut and stimulates peristalsis.
 1
It 
has been found that patients with diarrhea symptoms do not reabsorb the serotonin from the gut 
properly, therefore over stimulating the intestines and producing diarrhea.
1
 
Treatment methods depend on the symptoms of patients. Physicians often recommend to 
patients beginning treatment with an alteration of diet. For example, food items such as coffee, 
legumes, and artificial sweeteners have been found to aggravate symptoms, particularly in 
patients with diarrhea symptoms.
1
For patients with constipation symptoms, patients are 
recommended to increase fiber to 30g a day and consume probiotics.
 1,4
 Other non-
pharmacologic treatments involve stress management or hypnotherapy.
 1  
Pharmacologic treatment approaches IBS from different aspects of the pathophysiology 
behind the condition. For example, anti-diarrheal medications are the first line drugs of choice 
for patients with diarrhea.
 1
 Anti-spasmodic use is still somewhat controversial. It has been found 
that this class of drugs may help to alleviate pain by decreasing the amount of intestinal 
cramps.
1
This paper evaluates three randomized controlled trials(RCT) for the effectiveness of 
antidepressant use in decreasing symptoms and improving quality of life for patients with IBS. 
 
Objective  
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The objective of this selective EBM review is to determine whether or not the use of 
antidepressants decreases symptoms and improves the quality of life in patients with IBS. 
Methods 
The criteria for selection involved a population of men and women between the ages of 
18 and 75 who meet the Rome II criteria of IBS. The intervention used was three different 
antidepressants including imipramine, citalopram, and St. John’s Wort. The experimental group 
was compared to an identical placebo given to the control group. The outcomes measured were 
improvement of IBS symptoms, in regards to frequency and severity, and increased quality of 
life. The types of studies used were RCTs. 
Key words used to find literature were irritable bowel syndrome, antidepressant use, and 
quality of life. All articles were published in the English language. All articles were published in 
peer review journals after the year 2009 and there were at least three articles published after the 
meta-analysis which was published in 2008. Research for articles was completed by me using 
PubMed and OVID after using the Cochrane database. Articles were selected based on relevance 
to the subject of interest and the outcomes measured in relationship to the patient, or a POEM. 
All articles chosen were randomized, controlled double blind studies. Articles were excluded in 
the studies if the patients were under 18 years old or if the results were not measured based on 
patient outcome. The statistics that were used in the articles were confidence interval(CI), p 
values, relative risk reduction(RRR), absolute risk reduction(ARR), numbers needed to treat 
(NNT), numbers needed to harm (NNH). Table 1 demonstrates the demographics included in the 
studies. 
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Table 1 - Demographics & Characteristics of included studies 
Study Type # of 
pts 
Age Inclusion Exclusion w/d intervention 
Saito et 
al., 2010 
RCT 70 18-70 Pts that meet 
the Rome II 
criteria for IBS 
Concurrent GI diagnosis; 
symptoms of severe 
depression; MR; past or 
current Hx of psychotic 
d/o; current use of 
mood/pain or symptom 
altering meds- planned 
surgery during trial; 
allergy to St. John’s 
wort; any current chronic 
or acute diseases; ETOH 
abuse; professional 
drivers or operators of 
heavy equipment; major 
CV events in the last 6 
mo; use of IBS drugs in 
the past 30 day 
10 Double blind 
Randomized  
450 mg BID 
St. John’s 
Wort  vs. 
placebo. 
Abdul-
Bakiet 
al., 2009 
RCT 107 >18 
y/o 
Pts that meet 
the rome II 
criteria for IBS 
and have an 
unsatisfactory 
response to 1+ 
prescription 
antispasmodics 
available on 
the Lebanese 
market  
< 18 y/o; allergy to 
imipramine; Hx of 
melena/hematochezia/wt 
loss/cardiac arrhythmias; 
any use drugs of drugs 
that could change bowel 
habits; lactose 
intolerance; use of 
antidepressants; clinical 
depression 
51 Double blind 
randomized, 
25 mg tablet 
of imipramine 
vs identical 
placebo 
Ladabau
m et al. , 
2010 
RCT 54 18-75 
y/o 
Pts that meet 
the rome II 
criteria for 
IBS;good 
health; normal 
sigmoidoscopy
/colonoscopy 
w/in 5 yrs; 
normal CBC 
and TFS  
Depression or use of 
antidepressants; 
pregnancy; use of IBS 
medication/antispansmod
ics/anticholinergics; 
chronic pain meds using 
opiates; prior rectal/colon 
surgery; major organ 
disease 
9 Double blind  
randomized, 
20 mg 
citalopram vs 
identical 
placebo 
Information from Saito YA., Abdul-Baki H., and Ladabaum U. was used in the above 
table. 
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Outcomes measured 
Outcomes measured were based on patient-oriented problems. In the study using St. 
John’s Wort(SJW), outcomes were measured using a bowel symptoms score (BSS) and IBS 
quality of life (IBS-QoL).
 5 
The BSS was based on pain, bloating, constipation and diarrhea. The 
IBS-QoL has thirty-four questions assessing quality of life.
5
 The imipramine study used the IBS-
QoL, as well as, a SF-36 questionnaire.
6 The citalopram study used Beck’s Depression Inventory, 
daily symptom scoring on a scale from 1-10, IBS-QoL, and a barostat study to assess outcomes.
7 
Results 
The results were presented in dichotomous data for all three articles. The study using SJW 
randomly assigned participants to a group using 450 mg of SJW by mouth twice a day or an 
identical placebo for twelve weeks.
5
 Patients were asked to evaluate their symptoms on a BSS 
and IBS-QoL prior to the start of the study and again at twelve and twenty-four weeks after the 
start of the study. The study also assessed depression symptoms using center for epidemiological 
studies depression scale (CES-D).
5
  
In Saito et al., the mean change from the baseline BSS score decreased in both groups. 
However, it was found that the BSS in SJW was seventy-six compared to forty-four in the 
placebo group, indicating that the placebo group had a better outcome.
5
At twelve weeks, “51% 
of the study drug group compared to 54% of the placebo group felt that the drug had helped 
decrease the symptoms”. 5 The P value was .03(Table 2), the relative benefit increase (RBI) was -
.055, the absolute benefit increase (ABI) was -.03 and the number needed to treat (NNT) was -
34.
 5
 The negative NNT indicates that for every thirty-four patients who were treated with SJW, 
there would be one fewer patient that would have decreased symptoms or increased QoL than if 
they had been treated with placebo.
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The study using imipramine randomly assigned participants to a group using 25 mg of the 
drug by mouth once a day before bedtime or identical placebo for twelve weeks.
 6
 Patients were 
asked on week four, eight and twelve if they “had significant improvement in symptoms since 
the start of the study drug.” 6 At twelve weeks patients were asked to assess the QoL based on a 
SF-36 questionnaire. At week 16 a follow-up questionnaire was given to evaluate overall 
symptoms.
6
 In Abdul-Baki et al., “80.6% of the imipramine group compared to 48.0% of the 
placebo group” reported relief in IBS symptoms. The p-value, per protocol, was .053(Table 2), 
the RBI was .68, the ABI was .33, and the NNT was 4. This indicates that for every four patients 
treated with imipramine one more patient had decreased symptoms or improved QoL than if they 
had been treated with the placebo.   
In the study using citalopram, patients were randomly assigned to a group using 20 mg of the 
drug by mouth for the first four weeks or a group using identical placebo.
7
 After the first four 
weeks, patients were instructed to take two tablets for another four weeks, resulting in either 40 
mg of citalopram therapy or two tablets of placebo a day.
7
 If patients experienced side effects 
while on two tablet therapy they were instructed to decrease dose to one tablet a day. Prior to the 
start of the study, participants filled out the Beck’s Depression Inventory, daily symptom scoring 
on a scale from 1-10, IBS-QoL, and a barostat study.
 7
  
Throughout the study, questionnaires were given weekly to evaluate the symptoms on a scale 
from 1-10 and whether or not adequate relief had been achieved.
 
 At week eight of the study, 
participants completed a second IBS-QoL and barostat study.
7
Ladabaum U. et al. demonstrated 
that “44% in the citalopram group compared to 56% in the placebo group showed 
improvement.”7The P value was .59(Table 2) and there was a 95% CI .61-1.04, indicating that 
the treatment effect is precise.
 
The RBI was - .214, the ABI was -.12, and the NNT was -9.
7
 The 
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negative NNT indicates that for every nine patients who were treated with SJW, there would be 
one fewer patient that would have decreased symptoms or increased QoL than if they had been 
treated with placebo. 
Table 2 Comparison of study results 
5,6,7
 
Study Response 
in the study 
group 
Response 
in the 
control 
group 
RBI ABI  NNT P-value 
Ladabaum 
(2010) 
44% 56% -0.241 -0.12 -9 0.59 
Saito(2010) 51% 54% -0.055 -0.03 -34 0.03 
Abdul-
Baki(2009) 
80.6% 48.0% 0.68  .129 
 
4 <0.01 
Information from Saito YA., Abdul-Baki H., and Ladabaum U. was used in the above 
table. 
In the studies using SJW and citalopram the NNT was a negative value while the study 
using imipramine demonstrated a positive value for NNT. Of the three studies used, imipramine 
was the only drug that was found to improve symptoms and IBS-QoL. There were a high 
percentage of dropouts in the imipramine study. In the imipramine and placebo group, 14/59 and 
6/48, respectively, dropped out due to side effects.
 6
 Three of the fourteen participants that 
dropped out on the imipramine group due to adverse side effects reported sleep disturbance, 
making this the most common side effect.
 
A higher percentage of patients taking imipramine 
experienced adverse effects compared to placebo, “25% and 12.5%” respectively. 6 This indicates 
that the relative risk increase is 1.03, the absolute risk increase is .129, and the number needed to 
harm is 8.
6
 This indicates that for every eight people that are treated with imipramine, one person 
experiences an adverse effect. 
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Table 3-Reason for dropout in both study groups
6
 
 Imipramine (n= 59) Placebo (n=48) P-value 
Total dropouts 28 (47.5%) 23(47.9%) NS 
Premature withdrawl 8 (13.6%) 14 (29.2%) <0.05 
Lost to follow-up 3 (5.1%) 3 (6.3%) NS 
Protocol violation 3 0 NS 
Side effects 14 (23.7%) 6 (12.5%) 0.094 
 This table comes directly from Abdul-Baki H. et al. 
Discussion 
The RCT (Saito Y. et al.) assessing the efficacy of SJW to reduce IBS symptoms, determined 
that SJW was less effective than the placebo. The BSS, AR, and IBS-QoL measured all indicated 
similar results. There are very few well designed studies evaluating the use of herbal and 
alternative medicine. For example, there are no studies indicating what the appropriate dose of 
SJW is, therefore, producing an inconsistency in the study.
 5
 The population of this study may 
alter the results. The participants included were from a smaller area with both mild IBS 
symptoms and mood disorders. Patients with severe mood disorders were excluded from the 
study.
 5 
Also, this study is limited due the evaluation of all IBS subtypes. In theory, one subset 
may benefit over another but that issue was not addressed. Another limitation to this study is the 
inclusion of a majority females compared to male participants.
 5
 
In the RCT (Abdul-Baki H. et al.) assessing the efficacy of imipramine use for IBS 
symptoms, it was determined that the drug may provide relief. 
6
 The SF 36 assessment 
completed after the study indicated a rise in QoL
 6
 Limitations to the study include a lack of 
evaluation of baseline psychiatric illness prior to the start of the study.
 6
 Another issue in the 
study that limits the results is the possibility of “unblinding due to the presence of anticholinergic 
effects.” 6 The high drop-out rate is also a limitation to the study. Additionally, there is a large 
chance of a non-adherence to the medication throughout the trial.
 6
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In the RCT (Ladabaum U.) assessing the efficacy of citalopram use for IBS symptoms, it was 
determined that the drug was less effective than the placebo. A stipulation of the study is that the 
drug only evaluates non-depressed patients, which may affect the results reported.
 7
 One 
limitation to the study is the small sample size. Another limitation is the “possibility of 
unblinding due to side effects.” 7 
Conclusion 
Evidence regarding anti-depressant therapy for improving IBS-QoL and decreasing IBS 
symptoms is conflicting. Of the three RCTs used in this systematic review, only one of them 
concluded that the drug was effective for improving symptoms of IBS. The study using SJW 
stated that the therapy was less effective than the placebo. However, the study also stated that 
there are very few well-designed studies testing the efficacy of herbs and alternative treatments.
 5 
The study using citalopram also concluded that the drug was less effective than placebo for 
treatment of IBS symptoms.
 7
 The study using imipramine was the only therapy found to be 
effective. Lack of a specific antidepressant or class of antidepressants is a flaw in research for 
this systematic review. For further research, one would isolate the therapy that has been found to 
be effective and expand upon that. For example, sample size of the study can be increased to 
assess a larger population which would provide a better representation of a typical population. 
Additionally, it reasonable to design future studies using drugs with similar mechanism of action 
to that of imipramine, such as other tricyclic antidepressants. Further research is necessary to 
conclude whether or not antidepressant therapy is effective in decreasing symptoms and 
improving QoL in patients with IBS. 
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